Dr. Angel Yu is a specialty oncology care physician board certified in medical oncology, hematology and internal medicine at Inova Health System. She joined Inova in 2020 and has been in medical practice since 2012. Her area of interest is genitourinary cancers, which include prostate, bladder, kidney, and testicular cancers.
She completed her undergraduate education at the University of Pennsylvania with a major in biology, after which she received her doctorate in medicine at the Drexel University College of Medicine. She completed her internal medicine and hematology/oncology training at The George Washington University in Washington, D.C.
Prior to joining Inova, Dr. Yu worked as a medical oncologist and hematologist with Novant Health and CaroMont Health, both based in North Carolina. She is excited to return to the D.C. area to focus on providing compassionate, personalized and evidence-based oncology care to patients with genitourinary cancers.
Awards/Associations
- Alpha Omega Alpha Medical Honor Society
- American Society of Clinical Oncology
- Society for Immunotherapy of Cancer
Research and Publications
Yu, E & Erck, A & Aragon-Ching, JB. (2021). Advances in Systemic Therapy for Urothelial Cancer: Evolution of the Field. In HS Watanabe (Ed.), Horizons in Cancer Research, Volume 79 (pp. 131- 168). Nova Science Publishers, Inc. https://novapublishers.com/shop/horizons-in-cancerresearch-volume-79/
Yu EM, Kittai A, Tabbara I. Chronic Lymphocytic Leukemia: Current Concepts. Anticancer Res. 2015 Oct;35(10):5149-65.
Kittai A, Yu EM, Tabbara I. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission. BMJ Case Reports. 2014 Dec 23; doi:10.1136/bcr-2014-207466.
Yu EM, Kittai A, Aragon-Ching JB. Leiomyosarcoma: Risk Factors, Diagnosis and Treatment Options. 1st ed. New York: Nova Science Publishers; c2014. Chapter 2, Leiomyosarcomas of the Genitourinary Tract; p. 75-90.
El-Ayass W, Yu EM, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):144-7.
Yu EM, Jain M, Aragon-Ching JB. Angiogenesis inhibitors in prostate cancer therapy. Discov Med. 2010 Dec;10(55):521-30.
Yu EM, El-Ayass W, Aragon-Ching JB. The use of 5-alpha reductase inhibitors for the prevention of prostate cancer. Cancer Biol Ther. 2010 Jul 13;10(1).
Yu, E.-m.; Linville, L.; Rosenthal, M.; Aragon-Ching, J.B. A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines 2021, 9, 919. https://doi.org/10.3390/vaccines9080919
Eun-mi Yu & Jeanny B. Aragon-Ching (2022) Advances with androgen deprivation therapy for prostate cancer, Expert Opinion on Pharmacotherapy, 23:9, 1015-1033, DOI: 10.1080/14656566.2022.2033210
Yu EM, Belay S, Li W, Aragon-Ching JB. Non-urothelial and urothelial variants of bladder cancer [published online ahead of print, 2022 Nov 20]. Cancer Treat Res Commun. 2022;33:100661. doi:10.1016/j.ctarc.2022.100661
Yu E, Mudireddy M, Biswas R, Aragon-Ching JB. The role of switch maintenance therapy in urothelial cancers. Therapeutic Advances in Urology. 2023;15. doi:10.1177/17562872221147760
Yu EM, Hwang MW, Aragon-Ching JB. Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities. Res Rep Urol. 2023;15:519-529. https://doi.org/10.2147/RRU.S386517.
Eun-mi Yu et al., Racial differences and predictors of outcomes in testicular cancer based on the National Cancer Database (NCDB).. JCO 42, 503-503(2024).
DOI:10.1200/JCO.2024.42.4_suppl.503.
Eun-mi Yu et al., Metastatic testicular cancer (TC) presentations and outcomes: A contemporary analysis based on the National Cancer Database (NCDB).. JCO 42, e17016-e17016(2024).
DOI:10.1200/JCO.2024.42.16_suppl.e17016
Faran Polani, Min Woo Hwang, Eun-mi Yu, Hongkun Wang, and Jeanny B. Aragon-Ching., Analyzing disparities in socioeconomic factors, clinical characteristics, and outcomes in bladder cancer: Insights from the National Cancer Database (NCDB).. JCO 42, 4572-4572(2024).
DOI:10.1200/JCO.2024.42.16_suppl.4572
Aslanova M, Yu EM, Aragon-Ching JB. The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC). Explor Target Antitumor Ther. 2024;5:971–80. https://doi.org/10.37349/etat.2024.00258
Eun-mi Yu et al. Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).. J Clin Oncol 43, 622-622(2025).
DOI:10.1200/JCO.2025.43.5_suppl.622
Yu, E. M., Linville, L., Hwang, M. W., Kim, Y., Li, K., & Aragon-Ching, J. B. (2026). Harnessing genomic profiling for improved urothelial cancer outcomes. Expert Review of Anticancer Therapy, 26(1), 93–104. https://doi.org/10.1080/14737140.2025.2575827
Yildirim AM, Semler D, Harvell J, Yu EM, Jang S, Venna S. Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma. Front Oncol. 2025 Nov 10;15:1681839. doi: 10.3389/fonc.2025.1681839. PMID: 41293260; PMCID: PMC12640840.
Patient Reviews
About Patient Comments
The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.